Over 550 Total Lots Up For Auction at Three Locations - NC 04/05, CA 04/07, CA 04/17

The potential for Actinium in theranostics

by Philip F. Jacobus, CEO | October 13, 2021
My wife and I are taking some time off in New Mexico this week, so I did not conduct one of my usual video interviews. However, I did have an interesting phone call with my friend Peter Foti that I would like to share with you.

Those of you involved in nuclear medicine are already familiar with the concept of theranostics. It is a rapidly evolving field where a diagnostic radiopharmaceutical is combined with a therapeutic radiopharmaceutical to achieve a kind of personalized medicine that is tailored to the patient at the cellular level.

What fewer of you may be familiar with, is Actinium-225, and the potential it holds for theranostic applications and the treatment of cancer patients:

If you are interested in learning more about Actinium, I encourage you to check out a few of these articles we have written, and press releases we have shared on our site:

View all The Jacobus Report Blog Posts

About Phil Jacobus

Phil Jacobus has been involved in health care since 1977, when he visited China to sell equipment. He has done business in 35 countries and still travels extensively. Phil is active in charity, helps rural clinics and always tries to help DOTmed users when he can.

Phil is a member of AHRA, HFMA, AAMI and the Cryogenic Society of America. He has contributed to a number of magazines and journals and has addressed trade groups.

Phil's proudest achievement is that he has been happily married to his wife Barbara since 1989, who helped him found DOTmed in 1998.

You Must Be Logged In To Post A Comment